TREATMENT DATABASE

Gabitril (generic: tiagabine) is a selective GABA reuptake inhibitor used to treat seizure disorders.

Gabitril was first developed in 1988 by the Danish pharmaceutical company, Novo Nordisk. Currently, it is approved by the FDA for the treatment of partial seizures, although doctors prescribe it for treating panic disorder and neuropathic pain (including fibromyalgia). Gabitril is also used in combination with antidepressants and benzodiazepines for treating anxiety.

USES IN ME/CFS: Dr. Goldstein considers Gabitril to be safe and effective at low doses. He cautions that if the dose is increased too rapidly, patients may become delirious or manic.

Some patients report that Gabitril is a “wonder drug” for treating insomnia. Patients also report a reduction in pain and fatigue. Other patients report either no effect at all, or excessive sedation. The most frequently reported side effects of Gabitril are sedation, increase in “brain fog,” and gastric upset, and, in doses over 8 mg, tingling (paresthesia) in the hands. Gabitril can induce seizures in those without previous seizure disorder, particularly in people taking other GABA enhancers.

Treatment rating for Gabitril (tiagabine)